X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-14
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37419,647-   
Low Rs12911,984-   
Sales per share (Unadj.) Rs197.83,537.9-  
Earnings per share (Unadj.) Rs21.2-441.5-  
Cash flow per share (Unadj.) Rs34.7324.6-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.97,673.6-  
Shares outstanding (eoy) m80.69265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.5 28.5%   
Avg P/E ratio x11.9-35.8 -33.1%  
P/CF ratio (eoy) x7.248.7 14.9%  
Price / Book Value ratio x1.42.1 67.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3064,205,366 0.5%   
No. of employees `0000.821.6 3.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.743,552.1 44.2%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-5,434.8 -38.0%   
INCOME DATA
Net Sales Rs m15,961940,725 1.7%  
Other income Rs m265-2,348 -11.3%   
Total revenues Rs m16,226938,377 1.7%   
Gross profit Rs m4,103120,850 3.4%  
Depreciation Rs m1,091203,701 0.5%   
Interest Rs m94429,672 3.2%   
Profit before tax Rs m2,334-114,872 -2.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-8,426 0.0%   
Tax Rs m624-5,906 -10.6%   
Profit after tax Rs m1,711-117,393 -1.5%  
Gross profit margin %25.712.8 200.1%  
Effective tax rate %26.75.1 519.8%   
Net profit margin %10.7-12.5 -85.9%  
BALANCE SHEET DATA
Current assets Rs m11,018495,642 2.2%   
Current liabilities Rs m9,517361,468 2.6%   
Net working cap to sales %9.414.3 65.9%  
Current ratio x1.21.4 84.4%  
Inventory Days Days11058 190.5%  
Debtors Days Days3566 52.6%  
Net fixed assets Rs m16,304114,872 14.2%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5162,040,399 0.7%   
Long term debt Rs m4,1891,069,209 0.4%   
Total assets Rs m29,8053,739,379 0.8%  
Interest coverage x3.5-2.9 -120.9%   
Debt to equity ratio x0.30.5 55.1%  
Sales to assets ratio x0.50.3 212.9%   
Return on assets %8.9-2.3 -379.8%  
Return on equity %11.8-5.8 -204.9%  
Return on capital %17.5-3.0 -582.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786161,541 1.7%  
From Investments Rs m-1,529-386,791 0.4%  
From Financial Activity Rs m-941217,320 -0.4%  
Net Cashflow Rs m316-7,929 -4.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.02 Rs / USD

Compare DISHMAN PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: NOVARTIS  SANOFI INDIA  FRESENIUS KABI ONCO.  ABBOTT INDIA  PLETHICO PHARMA  



Today's Market

Sensex Trades Over 250 Points Up; Tata Motors & Power Grid Top Gainers(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading higher by 252 points and the NSE Nifty is trading higher by 59 points.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - PFIZER COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS